Keywords
Acknowledgements
References
-
1.
Perry AM, Attar EC. New insights in AML biology from genomic analysis. Semin Hematol. 2014;51(4):282-97. [PubMed ID: 25311741]. https://doi.org/10.1053/j.seminhematol.2014.08.005.
-
2.
Graubert T, Stone R. AML genomics for the clinician. Semin Hematol. 2014;51(4):322-9. [PubMed ID: 25311744]. https://doi.org/10.1053/j.seminhematol.2014.08.006.
-
3.
Cassese A, Guindani M, Vannucci M. A bayesian integrative model for genetical genomics with spatially informed variable selection. Cancer Inform. 2014;13(Suppl 2):29-37. [PubMed ID: 25288877]. https://doi.org/10.4137/CIN.S13784.
-
4.
Lee KF, Weng JT, Hsu PW, Chi YH, Chen CK, Liu IY, et al. Gene expression profiling of biological pathway alterations by radiation exposure. Biomed Res Int. 2014;2014:834087. [PubMed ID: 25276823]. https://doi.org/10.1155/2014/834087.
-
5.
Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Blake Gilks C, et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology. 2014. [PubMed ID: 25308272]. https://doi.org/10.1111/his.12581.
-
6.
Seidabadi A, Rezatofighi SE, Motamedi H, Rashidi I. R462Q Mutation in Prostate Cancer Specimens. Gene Cell Tissue. 2014;1(2).
-
7.
Lin E, Chien J, Ong FS, Fan JB. Challenges and opportunities for next-generation sequencing in companion diagnostics. Expert Rev Mol Diagn. 2014:1-17. [PubMed ID: 25249308]. https://doi.org/10.1586/14737159.2015.961916.
-
8.
Lohmann K, Klein C. Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics. 2014;11(4):699-707. [PubMed ID: 25052068]. https://doi.org/10.1007/s13311-014-0288-8.
-
9.
Stasiewicz D, Staroslawska E, Brzozowska A, Mocarska A, Losicki M, Szumilo J, et al. [Epidemiology and risk factors of the prostate cancer]. Pol Merkur Lekarski. 2012;33(195):163-7. [PubMed ID: 23157136].
-
10.
Demichelis F, Stanford JL. Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol. 2014. [PubMed ID: 24996773]. https://doi.org/10.1016/j.urolonc.2014.04.021.
-
11.
Karyadi DM, Zhao S, He Q, McIntosh L, Wright JL, Ostrander EA, et al. Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families. Int J Cancer. 2014. [PubMed ID: 25273821]. https://doi.org/10.1002/ijc.29241.
-
12.
San Francisco IF, Rojas PA, Torres-Estay V, Smalley S, Cerda-Infante J, Montecinos VP, et al. Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population. J Cell Mol Med. 2014;18(1):125-33. [PubMed ID: 24224612]. https://doi.org/10.1111/jcmm.12171.
-
13.
Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, Alvarez JC, Lorente JA, Cozar JM. [RNASEL study of genetics of prostate cancer and its relation to clinical staging]. Actas Urol Esp. 2012;36(5):306-11. [PubMed ID: 22464196]. https://doi.org/10.1016/j.acuro.2011.12.002.
-
14.
Li SX, Barrett BS, Harper MS, Heilman KJ, Halemano K, Steele AK, et al. Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection. Virology. 2013;443(1):134-42. [PubMed ID: 23725696]. https://doi.org/10.1016/j.virol.2013.05.009.
-
15.
Jin W, Wu DD, Zhang X, Irwin DM, Zhang YP. Positive selection on the gene RNASEL: correlation between patterns of evolution and function. Mol Biol Evol. 2012;29(10):3161-8. [PubMed ID: 22513284]. https://doi.org/10.1093/molbev/mss123.
-
16.
Shkedi-Rafid S, Dheensa S, Crawford G, Fenwick A, Lucassen A. Defining and managing incidental findings in genetic and genomic practice. J Med Genet. 2014;51(11):715-23. [PubMed ID: 25228303]. https://doi.org/10.1136/jmedgenet-2014-102435.
-
17.
Zhao J, Zhu Y, Boerwinkle E, Xiong M. Pathway analysis with next-generation sequencing data. Eur J Hum Genet. 2014. [PubMed ID: 24986826]. https://doi.org/10.1038/ejhg.2014.121.